Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
Introduction Multiple myeloma (MM) is a hematological malignancy characterized by terminally differentiated plasma cells (PCs), immunosuppression and end-organ damage. Despite the therapeutic progress achieved with the introduction of the proteasome inhibitors, immunomodulators and monoclonal antib...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-09-01
|
Series: | Hematology Reports |
Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8921 |